AstraZeneca announced that Robert Iannone would be taking over its immuno-oncology drug development operations, a little more than a month after former senior vice president and head of immuno-oncology Rachel Humphrey left the company for undisclosed personal reasons at the end of November 2014. At about the same time, Peter Emtage, who was part of AstraZeneca’s MedImmune unit, left the company to take a senior position at West Palm Beach, Florida.-based Intrexon Corporation.
The departures were unrelated and did not impact AstraZeneca’s immuno-oncology business, according to the company.
Advertisement
